Managing Risk in the New World by Kaplan, R, Mikes, A, Simons, R, Tufano, P, Hofmann, M

Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option. by Maughan, T, Adams, R, Wilson, R, Seymour, M, Meade, A, Kaplan, R

Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN stud... by Wood, G, Grenader, T, Nash, S, Adams, R, Kaplan, R, Fisher, D, Maughan, T, Bridgewater, J

BRAF and NRAS locus-specific variants have different outcomes on survival to colorectal cancer by Summers, MG, Smith, CG, Maughan, TS, Kaplan, R, Escott-Price, V, Cheadle, JP

Evaluating many treatments and biomarkers in oncology: a new design. by Kaplan, R, Maughan, T, Crook, A, Fisher, D, Wilson, R, Brown, L, Parmar, M

Frequency scaling of the lower-hybrid current drive density limit in tokamak plasmas by Mayberry, M.J., Porkolab, M., Chen, K.I., Fisher, A.S., Griffin, D., Kaplan, R.

Get full text

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. by Adams, R, Meade, A, Madi, A, Fisher, D, Kay, E, Kenny, S, Kaplan, R, Maughan, T

Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. by Vale, C, Tierney, J, Fisher, D, Adams, R, Kaplan, R, Maughan, T, Parmar, M, Meade, A

A NOVEL COLORECTAL CANCER SUSCEPTIBILITY SNP IN THE EIF3H PROMOTER INFLUENCES PATIENT SURVIVAL AND RESPONSE TO TREATMENT by Cheadle, J, Smith, C, Fisher, D, Maughan, T, Moskvina, V, Meade, A, West, H, Kaplan, R

Impact of K-ras status on the effects of EGFR-targeted monoclonal antibody (MAb) therapy in advanced colorectal cancer (ACRC): A systematic review and meta-analysis of randomized c... by Vale, C, Tierney, J, Meade, A, Fisher, D, Kaplan, R, Adams, R, Maughan, T, Parmar, M

A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS (RCTS) OF EGFR-TARGETED MONOCLONAL ANTIBODY (MAB) THERAPY IN ADVANCED COLORECTAL CANCER (ACRC): IMPACT OF K-RA... by Vale, C, Tierney, J, Meade, A, Fisher, D, Kaplan, R, Adams, R, Maughan, T, Parmar, M

Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis by Vale, C, Tierney, J, Fisher, D, Adams, R, Kaplan, R, Maughan, T, Parmar, M, Meade, A

HIGH THROUGHPUT SOMATIC PROFILING OF THE RAS-RAF-MAP AND PI3K-PTEN-AKT PATHWAYS IN ADVANCED COLORECTAL CANCER AND CORRELATIONS WITH RESPONSE TO CETUXIMAB by Smith, C, Claes, B, Fisher, D, Adams, R, Kaplan, R, Meade, A, Lambrechts, D, Maughan, T, Cheadle, J

THE IMPACT OF MILD RENAL IMPAIRMENT ON THE TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINE REGIMENS: EXPERIENCE IN THE MRC COIN TRIAL by Madi, A, Wilson, R, Adams, R, Seymour, M, Meade, A, Cassidy, J, Fisher, D, Kenny, S, Kaplan, R, Maughan, T

THROMBOCYTOSIS AS A PREDICTIVE AND PROGNOSTIC MARKER IN ADVANCED COLORECTAL CANCER (ACRC): RESULTS OF THE MRC COIN TRIAL EXPLORED by Maughan, T, Wilson, R, Seymour, M, Meade, A, Fisher, D, Kenny, S, Smith, C, Cheadle, J, Kaplan, R, Adams, R

INTERMITTENT VS. CONTINUOUS OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN THE MRC COIN TRIAL IN ADVANCED COLORECTAL CANCER: UPDATED EFFICACY RESULTS, QUALITY OF LIFE AND POTENTIAL P... by Adams, R, Wilson, R, Seymour, M, Meade, A, Madi, A, Cassidy, J, Fisher, D, Kenny, S, Kaplan, R, Maughan, T

Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma. by Fairfax, B, Pratap, S, Roberts, I, Collier, J, Kaplan, R, Meade, A, Ritchie, A, Eisen, T, Macaulay, V, Protheroe, A

Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN) by Adams, R, Wilson, R, Seymour, M, Meade, A, Madi, A, Cassidy, J, Fisher, D, Kenny, S, Kaplan, R, Maughan, T

THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBS... by Maughan, T, Adams, R, Smith, C, Seymour, M, Wilson, R, Meade, A, Fisher, D, Madi, A, Cheadle, J, Kaplan, R

Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN... by Maughan, T, Adams, R, Smith, C, Seymour, M, Wilson, R, Meade, A, Fisher, D, Madi, A, Cheadle, J, Kaplan, R